Efficacy of Intralesional Platelet Rich Plasma in Patients of De Quervain's Tenosynovitis

Efficacy of Intralesional Platelet Rich Plasma in Patients of De Quervain's Tenosynovitis

De Quervain's tenosynovitis (DQT) was originally identified by Swiss surgeon Fritz de Quervain in 1895. It is a condition involving the entrapment of tendons within the first dorsal compartment of the wrist. In DQT, the sheaths surrounding the abductor pollicis longus (APL) and extensor pollicis brevis tendons thicken as they pass through a fibro-osseous tunnel near the radial styloid of the distal wrist. This thickening leads to pain, which worsens with thumb movements and radial or ulnar deviation of the wrist. Traditional treatment methods, such as corticosteroid injections and physical therapy, often provide only temporary relief and may not address the underlying inflammation effectively. Intralesional platelet rich plasma (PRP) therapy has emerged as a promising alternative, utilizing the patient's own growth factors and cytokines to promote healing and reduce inflammation. By investigating the efficacy of intralesional PRP in patients with DQT, this research aims to provide evidence for a minimally invasive treatment option that could enhance recovery times, reduce pain, and improve functional outcomes.

Inclusion Criteria:

• Either gender,
• Aged between 18 and 60 years
• Presenting with de quervain's tenosynovitis

Exclusion Criteria:

• Previous surgery or intervention forde quervain's tenosynovitis
• Local skin infection or osteomyelitis
• Pregnant or lactating mothers